Skye Bioscience extends credit agreement maturity to Feb 28, 2023 or sale of Verdélite Sciences

Skye Bioscience, Inc.

Amendment No. 5 to Multi Draw Credit Agreement with Emerald Health Sciences extends maturity to earlier of sale of Verdélite Sciences, Feb 28, 2023, or termination date.
Director Bobby Rai appointed to Nominating and Corporate Governance Committee on January 5, 2023.
Credit agreement originally dated April 1, 2020, previously amended in March, September, and November 2022.

item 1.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Skye Bioscience, Inc. amended Credit Agreement Amendment with Emerald Health Sciences, Inc. (effective 2022-12-30).

Action: amendment
Agreement: credit facility
Counterparty: Emerald Health Sciences, Inc.
Effective: 2022-12-30

Exact text from the filing

On December 30, 2022, Skye Bioscience, Inc. (the "Company") entered into Amendment No. 5 (the "Credit Agreement Amendment") to the Amended and Restated Multi Draw Credit Agreement (as amended, the "Credit Agreement") with Emerald Health Sciences, Inc. ("Sciences").

View on SEC.gov

Browse all material agreements →

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001516551-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.